Podcast on Dupuytren's Disease: Pathology and Management

Kapitoly

A Viking's Inheritance

What's Actually Happening

The Table Top Test

Dupuytren's Diathesis

The Viking Connection

Associated Conditions

Normal Hand Anatomy

From Fascia to Cords

The Central and Spiral Cords

Surgical Dangers and Variations

What Surgery Can (and Can't) Do

The 'Table Top' Test

A Tour of the '-ectomies'

Less Invasive Options

Beyond the Scalpel

The Enzyme at Work

Putting It to the Test

Safety and Side Effects

The Nodules Question

A Summary and Farewell

Přepis

Mia: Have you ever seen those TV shows about Vikings, or maybe even done one of those DNA tests and found out you have some Northern European ancestry?

Ben: It's pretty popular these days. People love finding out they have a bit of Viking in them.

Mia: Exactly! But what if I told you that along with that heritage, you might have inherited something else... something that could literally cause your fingers to curl up and get stuck?

Ben: Now that's a hook. And the reason that can happen comes down to a condition with a very tricky name: Dupuytren's disease.

Mia: You're listening to Studyfi Podcast. We've got our expert, Ben, here to break it down. So, Ben, what is this... Dupuytren's disease?

Ben: It sounds complicated, but the core idea is simple. It's a benign condition—meaning not cancerous—that affects the tissue in the palm of your hand. It's basically a type of fibromatosis.

Mia: Fibro-what-now? Let's translate that for the rest of us.

Ben: Fair enough. Think of the fascia in your palm. It's a layer of connective tissue, kind of like a fibrous sheet under your skin. In Dupuytren's, this tissue starts to thicken and change.

Mia: How does it start? Does it just happen overnight?

Ben: Not at all. It usually begins with a small, palpable lump or mass in the palm. This is called a Dupuytren's nodule. It might even be a little tender at first.

Mia: So just a lump. That doesn't sound too bad yet.

Ben: Right. But then, as that nodule develops, it forms these thick, rope-like cords that can extend up into the fingers. And here’s the key part: these cords start to shorten and tighten.

Mia: And when they shorten... they pull the fingers with them?

Ben: Exactly. They cause what we call flexion contractures. The fingers get pulled into a bent position, and you can't straighten them out. It most commonly affects the ring and pinky fingers—the fourth and fifth digits.

Mia: So your hand can get stuck in a permanently curled position. That sounds seriously debilitating.

Ben: It can be. It can make it hard to do simple things like shake someone's hand, put on gloves, or even just put your hand flat on a table.

Mia: You just mentioned putting your hand on a table. I've heard there's a specific test for this, right?

Ben: You got it. It's called the 'table top test', and it's brilliantly simple. A person with a positive test literally can't place their palm and all their fingers flat on a tabletop at the same time. There will be a gap.

Mia: Wow. So the diagnosis is mainly based on a physical exam?

Ben: Yes, a careful patient history and a physical examination are usually all that's needed. We look for those tell-tale nodules and cords and perform the table top test. We also use a device called a goniometer to measure the exact angle of the joint contracture.

Mia: So no need for fancy MRIs or X-rays?

Ben: Generally, no. The signs are so specific—what we call pathognomonic—that a biopsy or imaging isn't necessary for diagnosis. It's one of the rare tumorous conditions where we can be very confident just from the clinical signs.

Mia: Are there any exceptions?

Ben: A couple. If we suspect something else is going on, like osteoarthritis causing the joint to stiffen, we might get an X-ray. Or in a very rare case of an isolated nodule, an MRI might be used, but that's not the norm.

Mia: Is this something that affects everyone equally? Or are some people more at risk?

Ben: Great question. There's a concept called 'Dupuytren's diathesis'. 'Diathesis' is just a fancy word for a tendency or predisposition to a disease. And this group is at much higher risk for a severe, recurring form of the disease.

Mia: So who's in this, let's call it, the 'high-risk club'?

Ben: The high-risk club, I like that. It was originally defined by a surgeon named Hueston. It typically includes Caucasians, especially those with a positive family history. It also includes having the disease in both hands, being male, and having it start before age 50.

Mia: And you mentioned family history. Is this genetic?

Ben: Absolutely. It's one of the most common heritable connective tissue diseases in Caucasians. It's passed down in an autosomal dominant pattern, but with what we call variable penetrance.

Mia: Meaning what, exactly?

Ben: It means even if you have the gene, you might not develop the condition, or you might only get a very mild case. It's not a guarantee, just a much higher probability.

Mia: Okay, let's go back to the Vikings from the beginning. Is that connection real?

Ben: Oh, it's very real! The epidemiology is fascinating. The disease is overwhelmingly found in people of Northern European descent, particularly Celtic and Scandinavian. The theory is that where the Vikings and other Northern Europeans emigrated, they brought the gene with them.

Mia: That is wild. So it's sometimes called the 'Viking disease'?

Ben: That's its nickname. It's quite common in places like Norway—one study showed a 9% incidence in men there—and it's also seen in Japan, but it's extremely rare in people of African or other Asian descent.

Mia: So it's really a story of genetics and migration patterns. What about lifestyle factors? Does your job or an injury cause it?

Ben: That's a common misconception, even going back to Dupuytren himself. He thought it was from heavy manual labor. But modern studies haven't really backed that up. A person's job doesn't *cause* it.

Mia: But can it trigger it?

Ben: That's the important distinction. A single, significant injury *can* initiate the disease in someone who is already genetically predisposed. It’s like the gene is the loaded gun, and an injury can sometimes be the trigger that fires it.

Mia: Are there other health conditions that are linked to Dupuytren's?

Ben: Yes, there are several associated diseases. It's seen more frequently in people with diabetes, alcoholism, and epilepsy. Some studies also link it to smoking and certain vascular disorders.

Mia: So, does having diabetes cause it, for instance?

Ben: Not a cause-and-effect relationship. It's an association. The thinking is that these primary conditions might cause changes at a tissue or molecular level that make the cells in the hand more susceptible to the triggers that kickstart Dupuytren's.

Mia: Okay, so to recap: it's a thickening and shortening of the fascia in your palm, causing your fingers to curl. It's diagnosed with a simple physical exam, and it has a very strong genetic link to Northern European ancestry.

Ben: You've nailed it. And understanding that basic science—the genetics, the epidemiology, the cell biology—is crucial for understanding why it happens and how we approach treatment.

Mia: It really changes how you think about a condition when you know its history is tied to Viking migrations.

Ben: It certainly makes it more memorable for an exam, doesn't it? It's not just a disease; it's a piece of history written in your own hands.

Mia: So it's not just random tightening, there’s a specific process going on. Let's get into the nitty-gritty then, Ben. What's actually happening inside the hand?

Ben: Exactly. To really get it, we have to start with the normal anatomy. Think of the hand as having this intricate web of connective tissue… structures called fascia, ligaments, and bands.

Mia: Okay, so what's the difference between all of those? Sounds a bit like a construction site.

Ben: It kind of is! In your palm and fingers, you have these things called pretendinous bands and natatory ligaments. They’re all part of the normal blueprint.

Mia: And I see names here like Cleland’s and Grayson’s ligaments. What do they do?

Ben: Great question. Think of them as tiny anchors. They're retention ligaments that hold the skin in place. Cleland’s ligaments are on the back side of the neurovascular bundle—that's the nerve and blood vessel package—and Grayson's are on the palm side.

Mia: So how does that normal, healthy tissue turn into a problem in Dupuytren's?

Ben: This is the key part. That normal, thin fascial tissue starts to thicken and clump together. It transforms into what we call a pathologic cord. These cords are the villains of the story.

Mia: So a normal band becomes an evil cord. Got it.

Ben: Pretty much! It's like thin threads weaving themselves into a thick, tight rope. And these ropes start to pull the fingers down. The most common ones are the pretendinous cord, central cord, and the spiral cord.

Mia: Let's talk about those. What makes a central cord so problematic?

Ben: The central cord often causes bending at both the knuckle and the middle joint of the finger—the MP and PIP joints. It attaches all the way down to the base of the middle phalanx, so its pull is really powerful.

Mia: And you mentioned a spiral cord? That sounds... complicated.

Ben: It is. The spiral cord is the one surgeons have to be most careful with. It's formed from five different normal structures that all coalesce into one pathologic cord.

Mia: Why is it so dangerous?

Ben: Because as it shortens, it pulls the neurovascular bundle—the nerve and artery—into a really weird position. It pulls it up towards the skin and into the middle of the finger.

Mia: So a surgeon might accidentally cut the nerve? That's terrifying.

Ben: It’s a huge risk. The nerve can be the very first thing you encounter right under the skin, instead of being safely tucked away. The spiral cord literally wraps around it.

Mia: Wow. So identifying which cord you're dealing with is critical for the treatment.

Ben: Absolutely. And it's not always the same. For the little finger, about a quarter of patients have a totally different cord called the abductor digiti minimi cord. It actually comes from a tendon.

Mia: So every case is a unique puzzle. Which makes diagnosing these contractures really important... I'm guessing that's what we should dive into next?

Mia: ...so that's how this disease can literally tie your hand in knots. But the big question is, what can we do about it? Can we untie those knots?

Ben: That's the million-dollar question, Mia. And for a long time, surgery was pretty much the only answer. There was a famous surgeon, John Hueston, who said his dream was that one day Dupuytren's would be treated *without* surgery.

Mia: A noble dream! Are we there yet?

Ben: We're getting closer. But for now, surgery is still a major player.

Mia: Okay, so when we talk about surgery, what's the actual goal? Are we talking about a complete cure?

Ben: That's a super important point. The goal of surgery is NOT to cure Dupuytren's disease. We can't actually eliminate it.

Mia: Oh, really? So what are surgeons trying to do then?

Ben: The goal is to release the joint contractures—to straighten the finger—and improve the hand's function. We're managing the symptoms, not getting rid of the underlying disease process.

Mia: So it could come back?

Ben: It definitely can. The recurrence rate is actually pretty high, somewhere between 20 and 80 percent depending on the patient and the procedure. It's a crucial thing for patients to understand.

Mia: So how does a doctor decide it's time for surgery? Is there a tipping point?

Ben: There is. The main indication is when the contracture gets to a certain point. For the big knuckle, the MP joint, it's a contracture of 30 degrees or more.

Mia: And for the other knuckles?

Ben: For the middle knuckle, the PIP joint, it's 20 degrees or more. At that point, you start having real functional problems, like not being able to put your hand in your pocket.

Mia: I can see how that would get annoying fast.

Ben: Exactly. It's also when you'd have a positive 'table top test'.

Mia: The table top test? What's that?

Ben: It's simple! You try to place your hand flat on a table. If you can't because your finger is bent and pulling your palm up, the test is positive. It's a good sign that the contracture is starting to interfere with daily life.

Mia: So you shouldn't wait until it's really, really bent?

Ben: Please don't. The more severe the contracture gets, the harder the surgery is, and the less predictable the outcome becomes, especially for that middle PIP joint.

Mia: Okay, so a patient needs surgery. What are the options? I'm seeing a lot of words ending in '-ectomy'.

Ben: Yes, the 'ectomy' family is large in Dupuytren's surgery. The most common procedure is a limited or partial fasciectomy. That's where the surgeon goes in and removes the specific cord of diseased tissue that's causing the problem.

Mia: That sounds logical. Just take out the bad part.

Ben: Right. But in the past, they used to do something called a radical fasciectomy. They would try to remove *all* the fascia in the palm, even the healthy-looking stuff.

Mia: That sounds... thorough.

Ben: It was! The idea was to prevent recurrence. But it turned out to cause more complications and didn't really stop the disease from coming back. It was a bit too aggressive.

Mia: So bigger isn't always better.

Ben: Definitely not here. Then there's another approach for aggressive cases called a dermofasciectomy.

Mia: Dermo... so that involves skin?

Ben: Exactly. The surgeon removes both the diseased fascia AND the overlying skin. Then they cover the area with a skin graft.

Mia: Whoa, why would they do that?

Ben: Think of the skin graft as a 'fire break'. It creates a barrier of new, uninvolved tissue that makes it much harder for the disease to recur in that spot. It's a great option for younger patients with really aggressive, recurring disease.

Mia: Taking skin grafts sounds pretty intense. Are there any less invasive procedures?

Ben: There are. One is called a needle fasciotomy. It's done percutaneously, right through the skin.

Mia: So no big incisions?

Ben: Nope. The doctor uses a small needle to repeatedly perforate and cut the cord blindly. Then they'll manually straighten the finger to rupture it the rest of the way.

Mia: Wow. The recovery must be way faster.

Ben: It is. People can often use their hand again within a week. But here's the catch... a big one.

Mia: I'm waiting for it...

Ben: The recurrence rate is about 58% at three years. So, you get a quick fix, but there's a very high chance you'll be dealing with it again soon.

Mia: Yikes! That's a huge trade-off.

Ben: It absolutely is. And that's why the decision is so patient-specific. For an older person who just needs a quick functional improvement and might not be a great candidate for a big surgery, it could be a perfect choice.

Mia: So it all comes back to the individual patient's needs, age, and goals.

Ben: One hundred percent. There's no single 'best' surgery for Dupuytren's. It's about matching the right tool to the right person to get them the best functional outcome.

Mia: So to recap, surgery aims to improve function, not provide a cure, and the choice of procedure is a very personal one based on a patient's specific situation. What a complex decision!

Ben: It is, and that's before we even get into what happens *after* the surgery. Hand therapy is a whole other critical piece of the puzzle...

Mia: And that's a fascinating look at the surgical side of things. But Ben, surgery isn't the only answer, right? For listeners who want to avoid the operating room, what are the options?

Ben: That's a great question, Mia. For a long time, surgery was the main event. But now, we have some really effective non-surgical treatments. One is called percutaneous needle fasciotomy, but it's not always great for severe cases.

Mia: Okay, so what's the big game-changer then?

Ben: The real star of the show is an enzyme. It's called clostridial collagenase. I know, it's a mouthful.

Mia: Sounds like something from a sci-fi movie! What does this enzyme actually do?

Ben: Think of it like a tiny demolition crew. The Dupuytren's cords are made of collagen. This enzyme, which comes from a bacterium, is injected directly into the cord. It specifically targets and breaks down that collagen.

Mia: So you inject it, and the cord just... dissolves? That seems too easy.

Ben: Almost! The injection happens on day one. The enzyme goes to work, weakening the collagen bonds in the cord. It's like turning a steel cable into a piece of cooked spaghetti.

Mia: I love that analogy! So what happens on day two?

Ben: On day two, the patient comes back. The doctor then gently, but firmly, straightens the finger. Because the cord is so weak, it usually just... snaps.

Mia: Snaps? You can actually hear it?

Ben: Sometimes you can! It’s a very distinct pop. And just like that, the finger can extend again. No major cutting involved. It's a procedure we call an enzymatic fasciotomy.

Mia: That sounds amazing. But how do we know it really works? Were there studies on this?

Ben: Oh yes, massive studies. Before the FDA would even consider it, this treatment went through rigorous testing. The two biggest trials were called CORD I and CORD II. Clever name, right?

Mia: Collagenase Option for Reducing Dupuytren’s. I see what they did there. So what did they find?

Ben: The results were pretty staggering. They compared the enzyme injection to a placebo, a fake injection. In the CORD I study, 64% of patients who got the enzyme had their finger corrected to almost perfectly straight.

Mia: Wow, 64 percent! What about the placebo group?

Ben: Get this… only about 7%. And the second study, CORD II, showed similar results. It was a clear, statistically significant win for the enzyme. It proved this wasn't just a fluke.

Mia: Okay, so it works. But is it safe? Injecting a flesh-eating-bacteria-adjacent enzyme sounds a little… risky.

Ben: It's much safer than it sounds. The most common side effects are what you'd expect from any injection: some pain, swelling, bruising, and maybe itching right at the site. These usually go away on their own.

Mia: That's reassuring. Any serious risks?

Ben: They are very rare. Out of more than 2,600 injections studied worldwide, there were only a handful of serious issues. The most notable was three cases of a tendon rupture.

Mia: A torn tendon sounds bad. Did they figure out why that happened?

Ben: They did. It happened when injecting a specific spot on the little finger. They've since modified the injection technique to be much more precise and avoid that area. The overall risk of that happening is incredibly low, about 0.2%.

Mia: Now, what about the nodules? The little lumps that often appear first. Do you inject those too?

Ben: That's a different story. Usually, we just watch the nodules. They can be a bit tender at first, but that often fades. For painful ones, some doctors have tried steroid injections, like triamcinolone.

Mia: And does that work?

Ben: It can. One study showed it shrunk the nodules in 97% of cases. But here's the catch… about half of them came back. So it's not a permanent fix, and it's not clear if it stops the disease from progressing.

Mia: So to recap our whole discussion today, Dupuytren's is a complex condition. We have traditional surgeries that cut the cord out, and now we have these incredible non-surgical options, especially the collagenase enzyme that just dissolves it from the inside.

Ben: Exactly. The key takeaway is that there are more tools in the toolbox than ever before. For many patients, an injection and a quick 'snap' the next day can achieve what used to require a full-blown surgery. It's a fantastic advancement.

Mia: It really is. Well Ben, that's all the time we have for today. Thank you so much for breaking all of this down for us. It was incredibly insightful.

Ben: My pleasure, Mia. It's always great to be here.

Mia: And a big thank you to our listeners for tuning in to the Studyfi Podcast. We hope you learned something new. Join us next time. Goodbye everyone!

Ben: Goodbye!